At what enterprise value was LAGARRIGUE acquired in 2021?

During the acquisition of LAGARRIGUE by NAXICAP PARTNERS in 2021, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 300M - 700M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of LAGARRIGUE when it was acquired by NAXICAP PARTNERS?

The estimated EV/EBITDA multiple for LAGARRIGUE is in the range of 15x - 25x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was LAGARRIGUE acquired by NAXICAP PARTNERS?

LAGARRIGUE was acquired by NAXICAP PARTNERS in 2021.

What was the revenue of LAGARRIGUE at the time of the deal?

The revenue of LAGARRIGUE at the time of the deal is estimated to be in the range of 100M - 200M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of LAGARRIGUE during the acquisition?

LAGARRIGUE's EBITDA is estimated to be in the range of 10M - 30M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the LAGARRIGUE acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the LAGARRIGUE deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.ardian.com/fr/communiques-de-presse/ardian-cede-sa-participation-majoritaire-dans-lagarrigue-naxicap-partners

← DATABASE

Home Database Healthcare & PharmaLAGARRIGUE

04/2021

LAGARRIGUE acquired by NAXICAP PARTNERS

FRANCE Life Sciences / Medical Devices / Implants & Prosthetics EV 300M - 700M EUR

Context

Naxicap Partners acquired a majority stake (~80%) in Groupe Lagarrigue from Ardian and iXO Private Equity. The management team reinvested to hold the remaining ~20%. Naxicap prevailed in a competitive auction process managed by Edmond de Rothschild Corporate Finance, beating out offers from IK Investment Partners and Cobepa. The transaction is financed through a unitranche debt facility (likely provided by ArcMont AM) combined with a PIK note (CIC Private Debt), including significant capex lines to fund future external growth.

In the past, the company had already been the subject of several LBOs, notably led by Azulis Capital / Bnp Paribas Developpement / Galia in 2011 and Ardian / Ixo Private Equity in 2016. This succession of buyouts highlights the strong attractiveness of the company's business model.

LAGARRIGUE, which reported an EBITDA margin of LOGIN in 2021, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Based in Toulouse, Lagarrigue is a leading French provider of external orthopaedic devices (prosthetics and orthotics). The group specializes in custom-made solutions (95% of activity) for patients with disabilities. Under previous ownership, it tripled its size, expanding into Switzerland, Belgium, and Spain, and digitized its operations through software subsidiaries (Rodin 4D, Vorum).

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2021

2020

Other operations with LAGARRIGUE

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
09/2016	ARDIAN / IXO PRIVATE EQUITY	LAGARRIGUE	FRANCE	Life Sciences	Ardian entered into exclusive negotiations to acquire a majority stake in Lagarrigue from Azulis Capital. The transaction allowed the management team to reinforce their equity stake. Historical minority investor iXO Private Equity reinvested, while Azulis Capital, Galia Gestion, and BNP Paribas Developpement fully exited
05/2011	AZULIS CAPITAL / BNP PARIBAS DEVELOPPEMENT / GALIA	LAGARRIGUE	FRANCE	Life Sciences	Following an initial OBO three years prior (where debt was fully repaid), Lagarrigue completed a majority LBO led by Azulis Capital. The consortium, including BNP Paribas Developpement, Galia Gestion, and historical investor iXO PE, acquired approximately 80% of the capital

REFERENCES

Valuation range: EV 300M - 700M EUR

Revenue range: 100M - 200M EUR

EBITDA range: 10M - 30M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of LAGARRIGUE by NAXICAP PARTNERS are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Target: lagarrigue

Acquirer: naxicap partners